Yale

Roy S. Herbst, MD, PhD, was honored by the International Association for the Study of Lung Cancer in recognition for his years of dedication and invaluable service to the organization and the lung cancer community.

Findings from a new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity, which could help develop a new treatment strategy to benefit patients with melanoma and other cancers.

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program.

A new study led by Yale Cancer Center scientists revealed the combination of ATR and PARP inhibitor therapies can effectively target the enzyme isocitrate dehydrogenase-I/2 (IDH-1/2) in mutant cancer cells.

Barbara Burtness, MD, has been appointed Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center.

Researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.

A revolutionary new urine screening test that utilizes a novel Keratin 17 cancer biomarker can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

Leading experts in cancer research and tobacco policy are not ready to recommend electronic nicotine delivery systems, like e-cigarettes, as a safe way to quit smoking.